Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: Case example nelfinavir

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 79, Issue 2, 2011, Pages 349-356

  Shono, Yasushi ^a,b   Jantratid, Ekarat ^a   Dressman, Jennifer B ^a  

^a GOETHE UNIVERSITY   (Germany)

^b TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

NELFINAVIR;

ALKALINITY; AREA UNDER THE CURVE; ARTICLE; COMPARTMENT MODEL; COMPUTER MODEL; COMPUTER PROGRAM; CRYSTALLIZATION; DIET RESTRICTION; DRUG SOLUBILITY; GASTROINTESTINAL TRACT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; PRECIPITATION; SMALL INTESTINE; SOLUBILITY; STOMACH EMPTYING;

EID: 80054989486     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2011.04.005     Document Type: Article

References (35)

1. J.B. Dressman, G.L. Amidon, C. Reppas, V.P. Shah, Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms, Pharm. Res. 15 (1998) 11-22. (Pubitemid 28080861)
2. D. Fleisher, C. Li, Y. Zhou, L.H. Pao, A. Karim, Drug, meal and formulation interactions influencing drug absorption after oral administration, clinical implications, Clin. Pharmacokinet. 36 (1999) 233-254. (Pubitemid 29178760)
3. B.N. Singh, Effects of food on clinical pharmacokinetics, Clin. Pharmacokinet. 37 (1999) 213-255. (Pubitemid 29452756)
4. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), Food-Effect Bioavailability and Fed Bioequivalence Studies, Guidance for Industry, 2002.
5. F. Hoffmann-La Roche Ltd., INVIRASE® Capsules (Saquinavir Mesylate), Complete Product Information, December, 2003.
6. Pfizer Inc. Canada, Product Monograph, Viracept®, www.pfizer.ca(Date of Revision: 10.09.06).
7. B. Kaeser, J.E. Charoin, M. Gerber, P. Oxley, H. Birnboeck, N. Saiedabadi, L. Banken, Assessment of the bioequivalence of two nelfinavir tablet formulations under fed and fasted conditions in healthy subjects, Int. J. Clin. Pharmacol. Ther. 43 (2005) 154-162. (Pubitemid 40424749)
8. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, Guidance for Industry, 2000.
9. T.T. Kararli, Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals, Biopharm. Drug Dispos. 16 (1995) 351-380.
10. Y. Wu, A. Loper, E. Landis, L. Hettrick, L. Novak, K. Lynn, C. Chen, K. Thompson, R. Higgins, U. Batra, S. Shelukar, G. Kwei, D. Storey, The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human, Int. J. Pharm. 285 (2004) 135-146. (Pubitemid 39361543)
11. N. Parrott, V. Lukacova, G. Fraczkiewicz, M.B. Bolger, Predicting pharmacokinetics of drugs using physiologically based modeling-application to food effects, AAPS J. 29 (2009).
12. E. Jantratid, N. Janssen, C. Reppas, J.B. Dressman, Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update, Pharm. Res. 25 (2008) 1663-1676.
13. M. Vertzoni, J. Dressman, J. Butler, J. Hempenstall, C. Reppas, Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds, Eur. J. Pharm. Biopharm. 60 (2005) 413-417. (Pubitemid 40922839)
14. E. Galia, E. Nicolaides, D. Horter, R. Lobenberg, C. Reppas, J.B. Dressman, Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs, Pharm. Res. 15 (1998) 698-705. (Pubitemid 28275645)
15. M. Vertzoni, A. Diakidou, M. Chatzilias, E. Soderlind, B. Abrahamsson, J.B. Dressman, C. Reppas, Biorelevant media to simulate fluids in the ascending colon of humans and their usefulness in predicting intracolonic drug solubility, Pharm. Res. 27 (2010) 2187-2196.
16. J.B. Dressman, C. Reppas, In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs, Eur. J. Pharm. Sci. 11 (2) (2000) S73-S80.
17. E. Nicolaides, E. Galia, C. Efthymiopoulos, J.B. Dressman, C. Reppas, Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data, Pharm. Res. 16 (1999) 1876-1882. (Pubitemid 30040705)
18. Y. Shono, E. Jantratid, N. Janssen, F. Kesisoglou, Y. Mao, M. Vertzoni, C. Reppas, J.B. Dressman, Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling, Eur. J. Pharm. Biopharm. 73 (2009) 107-114.
19. Y. Shono, E. Jantratid, F. Kesisoglou, C. Reppas, J.B. Dressman, Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans, Eur. J. Pharm. Biopharm. 76 (2010) 95-104.
20. K. Sugano, Introduction to computational oral absorption simulation, Expert Opin. Drug Metab. Toxicol. 5 (2009) 259-293.
21. R. Takano, K. Sugano, A. Higashida, Y. Hayashi, M. Machida, Y. Aso, S. Yamashita, Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test, Pharm. Res. 23 (2006) 1144-1156. (Pubitemid 43946137)
22. K. Thelen, E. Jantratid, J.B. Dressman, J. Lippert, S. Willmann, Analysis of nifedipine absorption from soft gelatin capsules using PBPK modeling and biorelevant dissolution testing, J. Pharm. Sci. 99 (2010) 2899-2904.
23. V.H. Sunesen, B.L. Pedersen, H.G. Kristensen, A. Mullertz, In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media, Eur. J. Pharm. Sci. 24 (2005) 305-313. (Pubitemid 40283513)
24. M. Longer, B. Shetty, I. Zamansky, P. Tyle, Preformulation studies of a novel HIV protease inhibitor, AG1343, J. Pharm. Sci. 84 (1995) 1090-1093.
25. S. Klein, The mini paddle apparatus? A useful tool in the early developmental stage? Experiences with immediate-release dosage forms, Dissolution Technol. 13 (4) (2006) 6-11.
26. P. Macheras, C. Reppas, J.B. Dressman, Biopharmaceutics of Orally Administered Drugs, Ellis Horwood Ltd., London, 1995.
27. V.H. Sunesen, R. Vedelsdal, H.G. Kristensen, L. Christrup, A. Mullertz, Effect of liquid volume and food intake on the absolute bioavailability of danazol, a poorly soluble drug, Eur. J. Pharm. Sci. 24 (2005) 297-303. (Pubitemid 40283512)
28. E. Nicolaides, M. Symillides, J.B. Dressman, C. Reppas, Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration, Pharm. Res. 18 (2001) 380-388. (Pubitemid 32595828)
29. K. Yamaguchi, Application of probability and statistics in chemical engineering, Kogyo Chosakai Publishing Co Inc., Tokyo, 1972.
30. B.J. Aungst, N.H. Nguyen, J.P. Bulgarelli, K. Oates-Lenz, The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds, Pharm. Res. 17 (2000) 1175-1180.
31. R. Takano, K. Furumoto, K. Shiraki, N. Takata, Y. Hayashi, Y. Aso, S. Yamashita, Rate-limiting steps of oral absorption for poorly water-soluble drugs in dogs; prediction from a miniscale dissolution test and a physiologically-based computer simulation, Pharm. Res. 17 (2008).
32. E.S. Kostewicz, M. Wunderlich, U. Brauns, R. Becker, T. Bock, J.B. Dressman, Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine, J. Pharm. Pharmacol. 56 (2004) 43-51. (Pubitemid 38195327)
33. K. Sugano, A simulation of oral absorption using classical nucleation theory, Int. J. Pharm. 378 (2009) 142-145.
34. L. Kalantzi, K. Goumas, V. Kalioras, B. Abrahamsson, J.B. Dressman, C. Reppas, Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies, Pharm. Res. 23 (2006) 165-176. (Pubitemid 43214673)
35. M. Morihara, N. Aoyagi, N. Kaniwa, S. Kojima, H. Ogata, Assessment of gastric acidity of Japanese subjects over the last 15 years, Biol. Pharm. Bull. 24 (2001) 313-315. (Pubitemid 32237176)